IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 71.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,688 shares of the medical research company’s stock after selling 50,038 shares during the quarter. Los Angeles Capital Management LLC’s holdings in IQVIA were worth $3,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Advisor Group LLC boosted its position in shares of IQVIA by 13.2% in the third quarter. Private Advisor Group LLC now owns 5,746 shares of the medical research company’s stock worth $1,362,000 after acquiring an additional 668 shares during the last quarter. International Assets Investment Management LLC raised its stake in IQVIA by 26,871.1% during the third quarter. International Assets Investment Management LLC now owns 40,996 shares of the medical research company’s stock worth $9,715,000 after purchasing an additional 40,844 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of IQVIA by 4.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 11,346 shares of the medical research company’s stock valued at $2,689,000 after purchasing an additional 530 shares during the last quarter. First Trust Direct Indexing L.P. grew its stake in shares of IQVIA by 19.9% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 10,825 shares of the medical research company’s stock valued at $2,565,000 after buying an additional 1,798 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of IQVIA during the 3rd quarter worth $111,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners restated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $186.40 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $32.82 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $184.66 and a 52 week high of $261.73. The stock has a 50 day moving average of $199.30 and a 200-day moving average of $215.26.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.